- •Ipragliflozin as an add-on therapy is effective in improving glycaemic control, with added benefits of some reductions in blood pressure, weight and TG levels.
- •Ipragliflozin as an add-on therapy was well tolerated, as neither the incidence of TEAEs nor drug-related TEAEs was significantly increased, and it also didn’t increase risk of urinary tract infections or genital infections.
- •Ipragliflozin as an add-on therapy do not appear cost-effective compared with metformin alone, but may be competitive against pioglitazone group and the sitagliptin + metformin group.
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Diabetes Research and Clinical Practice
- consensus statement by the american association of clinical endocrinologists and american college of endocrinology on the comprehensive type 2 diabetes management algorithm–2016 executive summary.Endocr Pract. 2016; 22: 84-113
- Ipragliflozin: first global approval.Drug. 2014; 74: 611-617
- Safety and efficacy of ipragliflozin in Japanese patients with type 2 diabetes in real-world clinical practice: interim results of the STELLA-LONG TERM post-marketing surveillance study.Expert Opin Pharmacother. 2018; 19: 189-201
- Efficacy of ipragliflozin as monotherapy or as add-on therapy with other oral antidiabetic medications for treating type 2 diabetes in Japanese patients with inadequate glycemic control: a subgroup analysis based on patient characteristics.J Diabetes Investig. 2018; 9: 341-353
- Combinational therapy with metformin and sodium-glucose cotransporter inhibitors in management of type 2 diabetes: Systematic review and meta-analyses.Diabetes Res Clin Pract. 2014; 105: 313-321
- Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis.Diabetes Obes Metab. 2016; 18: 783-794
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trials.BMJ. 2011; 343d5928
The Cochrane Collaboration. Cochrane handbook for systematic reviews of interventions (Version 5.1.0). March, 2011. [cited 2018 March 15]. Available from: http://handbook.cochrane.org.
- Measuring inconsistency in meta-analyses.BMJ. 2003; 327: 557-560
National Bureau of Statistics of China. Years data. 2018. [cited 2019 Jan 30]. Available from: http://data.stats.gov.cn/easyquery.htm?cn=C01&zb=A060J&sj=2017.
National Bureau of Statistics of China. Statistical Bulletin of National Economic and Social Development in 2017. 2018. [cited 2019 Jan 30]. Available from: http://www.stats.gov.cn/tjsj/zxfb/201802/t20180228_1585631.html.
- Efficacy and safety of ipragliflozin as an add-on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus: a randomized controlled trial.Diabetes Obes Metab. 2018; 20: 2408-2415
- Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, reduces bodyweight and fat mass, but not muscle mass, in Japanese type 2 diabetes patients treated with insulin: a randomized clinical trial.J Diabetes Investig. 2018;
- Efficacy and safety of ipragliflozin as add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): a multi-centre, randomized, placebo-controlled, double-blind study.Diabetes Obes Metab. 2016; 18: 1207-1216
- Efficacy and safety of ipragliflozin as an add-on to a sulfonylurea in Japanese patients with inadequately controlled type 2 diabetes: results of the randomized, placebo-controlled, double-blind, phase III EMIT study.Diabetol Int. 2015; 6: 125-138
- Ipragliflozin in combination with metformin for the treatment of Japanese patients with type 2 diabetes: ILLUMINATE, a randomized, double-blind, placebo-controlled study.Diabetes Obes Metab. 2015; 17: 304-308
- Efficacy and safety of ipragliflozin as an add-on to pioglitazone in Japanese patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study (the SPOTLIGHT study).Diabetol Int. 2015; 6: 104-116
- A randomized, double-blind, placebo-controlled study on long-term efficacy and safety of ipragliflozin treatment in patients with type 2 diabetes mellitus and renal impairment: results of the long-term ASP1941 safety evaluation in patients with type 2 diabetes with renal impairment (LANTERN) study.Diabetes Obes Metab. 2015; 17: 152-160
- Efficacy, safety, and tolerability of ipragliflozin in Asian patients with type 2 diabetes mellitus and inadequate glycemic control with metformin: results of a phase 3 randomized, placebo-controlled, double-blind, multicenter trial.J Diabetes Investig. 2016; 7: 366-373
- Addition of ipragliflozin to metformin treatment in Korean patients with type 2 diabetes mellitus: subgroup analysis of a phase 3 trial.Diabetes Metab J. 2017; 41: 135-145
- Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study.Diabetes Obes Metab. 2013; 15: 403-409
- A phase 3 randomized placebo-controlled trial to assess the efficacy and safety of ipragliflozin as an add-on therapy to metformin in Russian patients with inadequately controlled type 2 diabetes mellitus.Diabetes Res Clin Pract. 2018; 146: 240-250
- Efficacy and tolerability of canagliflozin as add-on to metformin in the treatment of type 2 diabetes mellitus: A meta-analysis.Eur J Clin Pharmacol. 2015; 71: 1325-1332
- Efficacy and safety of empagliflozin as add-on to metformin for type 2 diabetes: a systematic review and meta-analysis.Eur J Clin Pharmacol. 2016; 72: 655-663
- The effects of clinical and statistical heterogeneity on the predictive values of results from meta-analyses.Clin Microbiol Infect. 2014; 20: 123-129
- Tolerability and efficacy of ipragliflozin in the management of inadequately controlled type 2 diabetes mellitus: a systematic review and meta-analysis.Exp Clin Endocrinol Diabetes. 2018;
- The impact of intragastric balloons on obesity-related co-morbidities: a systematic review and meta-analysis.Am J Gastroenterol. 2017; 112: 429-439
- Effects of sodium-glucose cotransporter 2 inhibitor monotherapy on weight changes in patients with type 2 diabetes mellitus: a Bayesian network meta-analysis.Clin Ther. 2019; 41e311
- The role of sodium-glucose co-transporter 2 inhibitors in the treatment of type 2 diabetes.Clin Ther. 2015; 37: 1150-1166
- Ipragliflozin effectively reduced visceral fat in Japanese patients with type 2 diabetes under adequate diet therapy.Endocr J. 2016; 63: 589-596
- Exploring glycosuria as a mechanism for weight and fat mass reduction. a pilot study with remogliflozin etabonate and sergliflozin etabonate in healthy obese subjects.J Clin Transl Endocrinol. 2014; 1: e3-e8
- Effects of sodium-glucose co-transporter 2 (SGLT2) inhibition on renal function and albuminuria in patients with type 2 diabetes: a systematic review and meta-analysis.PeerJ. 2017; 2017e3405
- Sodium glucose cotransporter-2 selective inhibitors (SGLT2I) for retarding diabetic kidney disease progression: a systematic review and meta-analysis.Nephrol Dial Transpl. 2017; 32: iii264-iii265
- Ipragliflozin lowers small, dense low-density lipoprotein cholesterol levels in Japanese patients with type 2 diabetes mellitus.J Clin Transl Endocrinol. 2016; 6: 1-7
- Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of randomized controlled trials.Diabetes Obes Metab. 2017; 19: 348-355
- Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation.Health Technol Assess. 2017; 21: 1-218
American Diabetes Association. 8. Pharmacologic Approaches to Glycemic Treatment. Diabetes Care. 2017; 40: S64–S74.
- Elevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients: a meta-analysis of randomised controlled trials.Diabetologia. 2016; 59: 2546-2551